Cancer immunotherapy developer Elicio Therapeutics is finally getting a listing on the public markets to finance its clinical research. But rather than the traditional IPO it had been seeking, the ...

BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the ...

In a merger with troubled Angion Biomedica, Elicio Therapeutics has spied an opportunity to finally list on the Nasdaq as it prepares to push a cancer vaccine into phase 2 trials. The writing had been ...

Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology Lead program of the combined company will ...